NEOG:NSD-Neogen Corporation (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 14.43

Change

-0.01 (-0.07)%

Market Cap

USD 3.13B

Volume

0.93M

Analyst Target

USD 73.67
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared food products and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. The company was incorporated in 1981 and is headquartered in Lansing, Michigan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-04 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-2.76 (-0.66%)

USD 34.17B
ILMN Illumina Inc

+3.73 (+2.49%)

USD 23.86B
ICLR ICON PLC

-1.60 (-0.73%)

USD 18.82B
NTRA Natera Inc

-0.72 (-0.58%)

USD 15.36B
EXAS EXACT Sciences Corporation

+1.33 (+1.91%)

USD 13.02B
MEDP Medpace Holdings Inc

-1.60 (-0.50%)

USD 9.93B
RDNT RadNet Inc

+1.45 (+2.18%)

USD 5.00B
SHC Sotera Health Co

-0.06 (-0.38%)

USD 4.49B
VCYT Veracyte Inc

+0.67 (+1.95%)

USD 2.59B
GH Guardant Health Inc

+0.60 (+2.61%)

USD 2.52B

ETFs Containing NEOG

KATZ:XETRA 4.65 % 0.00 %

N/A

N/A
PETZ:SW 4.65 % 0.00 %

N/A

N/A
PETZ:LSE 4.62 % 0.00 %

N/A

N/A
SBB ProShares Short SmallCap6.. 0.00 % 0.95 %

-0.06 (0%)

N/A
SDD ProShares UltraShort Smal.. 0.00 % 0.95 %

-0.11 (0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -87.24% 6% D- 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.24% 6% D- 3% F
Trailing 12 Months  
Capital Gain -83.78% 10% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.78% 10% F 4% F
Trailing 5 Years  
Capital Gain -96.05% 7% C- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.05% 7% C- 2% F
Average Annual (5 Year Horizon)  
Capital Gain -25.59% 24% F 10% F
Dividend Return -25.59% 24% F 10% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.73% 84% B 55% F
Risk Adjusted Return -73.66% 18% F 9% A-
Market Capitalization 3.13B 82% B 84% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.